Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan - Top-Institutions - MDSpire

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

  • February 26, 2025

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Renal Cell Carcinoma
    • Targeted Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Kidney Cancer
    • Clinical Trials

  • #3

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Medical Oncology
    • Renal Cell Carcinoma
    • Experimental Therapeutics

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Kidney Cancer
    • Targeted Therapy

Original Source(s)

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

  • February 26, 2025

Related Content

Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia

Surgical Intervention for Emphysematous Osteomyelitis of the Spine in a Patient with Malnutrition and Anemia: A Unique Case Study

Clinical Findings in Migrants With Asymptomatic Plasmodium Infections